Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)

Brands containing Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated), food notes, and the most important drug interactions.

BRANDS

No registered brands found for this active ingredient.

FOOD NOTES

No food notes on record for this active ingredient.

MOST IMPORTANT INTERACTIONS

first 10 of 50

ErenumabMODERATE
The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated).
Expert view
TheophyllineMODERATE
The serum concentration of Theophylline can be increased when it is combined with Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated).
Expert view
2-MethoxyethanolMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with 2-Methoxyethanol.
Expert view
9-(N-methyl-L-isoleucine)-cyclosporin AMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Expert view
AbataceptMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.
Expert view
AbetimusMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Abetimus.
Expert view
ActeosideMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Acteoside.
Expert view
AdalimumabMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.
Expert view
AfelimomabMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Afelimomab.
Expert view
AldesleukinMINOR
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
Expert view